Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer

Basit Öğe Kaydı
dc.contributor.authorMutlu, Hasan
dc.contributor.authorMusri, Fatma Yalcin
dc.contributor.authorArtac, Mehmet
dc.contributor.authorKargi, Aysegul
dc.contributor.authorOzdogan, Mustafa
dc.contributor.authorBozcuk, Hakan
dc.date.accessioned2020-03-26T19:06:20Z
dc.date.available2020-03-26T19:06:20Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: We aimed to assess the efficacy of a metronomic regimen with cyclophosphamide and etoposide in heavily treated patients with metastatic breast cancer (MBC). Materials and Methods: A total of 77 patients with MBC used continuous oral cyclophosphamide 50 mg/day and oral etoposide given as 2 x 50 mg/day for 2 days per week, were analyzed retrospectively from Akdeniz University and Selcuk University. The patients with MBC are predominantly refractory to antracyclines, taxanes, and antimetabolites. Results: The patients were treated and followed between May 2005 and June 2014. The median progression-free and overall survival (PFS and OS) were 7.03 (5.06-8.99) and 32.5 (22.5-42.4) months, respectively. No prognostic factor was found for OS. Conclusions: Metronomic treatment regimen with cyclophosphamide and etoposide is a novel and effective strategy in heavily pretreated MBC patients. This regimen can be used in early or late steps as independently from prognostic factors. Moreover, it has very low toxicity and is cheap. Impressive survival data and low cost may make this regimen a highly preferable option.en_US
dc.identifier.doi10.4103/0973-1482.154008en_US
dc.identifier.endpage290en_US
dc.identifier.issn0973-1482en_US
dc.identifier.issn1998-4138en_US
dc.identifier.issue2en_US
dc.identifier.pmid26148586en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage287en_US
dc.identifier.urihttps://dx.doi.org/10.4103/0973-1482.154008
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32322
dc.identifier.volume11en_US
dc.identifier.wosWOS:000357935800009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMEDKNOW PUBLICATIONS & MEDIA PVT LTDen_US
dc.relation.ispartofJOURNAL OF CANCER RESEARCH AND THERAPEUTICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectBreast canceren_US
dc.subjectheavily treateden_US
dc.subjectmetronomicen_US
dc.subjectsurvivalen_US
dc.titleMetronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu